(BNGO) Bionano Genomics - Ratings and Ratios

Bionano Genomics, Inc. (NASDAQ:BNGO) is a leading provider of genome analysis solutions, offering tools for genomics labs to interpret and analyze data across various platforms. Their software enables the generation of detailed data visualizations, simplifying the identification of causal variants. The companys flagship product, Saphyr, is a sample-to-result solution for structural variation analysis using optical genome mapping, providing insights into genetic variation and function. The Saphyr system includes a single-molecule imager, nanochannel arrays for DNA linearization via Saphyr Chips, and Bionano Prep Kits for extracting and labeling ultra-high molecular weight DNA. Additionally, Bionano offers Saphyr and Bionano compute servers, as well as VIA software, which integrates analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics applications.

Beyond its core products, Bionano Genomics provides a range of testing and laboratory services. These include FirstStepDx PLUS, a chromosomal microarray for identifying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing; NextStepDx PLUS, an exome sequencing test for childhood developmental disorders; OGM-Dx HemeOne for hematologic disorders; OGM-Dx FSHD for facioscapulohumeral muscular dystrophy type 1; and comprehensive OGM-Dx postnatal and prenatal whole genome structural variation testing. Founded in 2003 and headquartered in San Diego, California, the company is a key player in the genomics tools and services sector. Web URL: https://www.bionano.com.

As of the latest data, Bionano Genomics trades on the NASDAQ under the ticker symbol BNGO. The company has a market capitalization of $11.20M USD, with a price-to-book ratio of 0.23 and a price-to-sales ratio of 0.34. The stocks average 20-day volume is 124,380 shares, with a last price of $4.08. Technical indicators show a 20-day simple moving average (SMA) of $4.91, a 50-day SMA of $8.48, and a 200-day SMA of $24.49, indicating recent downward momentum. The average true range (ATR) is 0.50, reflecting moderate volatility.

3-Month Forecast: Based on and , Bionano Genomics is expected to face continued stock price pressure due to its negative P/E ratio and declining SMA trends. However, its low P/S ratio suggests potential undervaluation. The stock may experience limited upside in the near term, with support levels potentially forming near $3.50. On the upside, increased adoption of its genomic testing services and partnerships could drive revenue growth, though profitability remains uncertain given high R&D expenses. The companys focus on rare genetic disorders and expanding applications in cancer research may position it for long-term growth despite short-term challenges.